Therapeutic Asset Ratings

228 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Extra-nodal Involvement, Large Mass	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Inno-206 Extra-nodal Involvement, Large Mass	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Iparomlimab Immune Checkpoint Inhibitors	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Iparomlimab QL1706	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Ipilimumab BRAF V600E	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Ipilimumab Cetuximab	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Ipilimumab Conversion Therapy	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Ipilimumab Dabrafenib	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Ipilimumab Ipilimumab N01	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Ipilimumab MSS (Microsatellite Stable)	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Ipilimumab Sintilimab	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Lparomlimab Hepatocellular Carcinoma	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Osimertinib Cell Cycle Deregulation	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Pyrotinib Pyrotinib	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Pyrotinib SHR-A1811	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Recombinant Human Adenovirus Type 5 Portal Vein Thrombosis	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Regorafenib Liver Metastasis	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Sacituzumab Tirumotecan EGFR Gene Mutation	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Sacituzumab Tirumotecan PD-L1 Positive	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Shr-A1811 SHR-A1811	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Surufatinib Neuroendocrine Carcinoma	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Surufatinib Exocrine Pancreatic Carcinoma	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Tagitanlimab PD-L1 Positive	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
TIPIRACIL First-line Treatment	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Toripalimab Gallbladder Cancer	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)

Showing 126 to 150 of 228 assets

PreviousPage 6 of 10Next